OXiGENE Announces Clinical Trials Data to be Presented At the 2008 Annual
Meeting of the American Society of Clinical Oncology
WALTHAM, Mass., May 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, announced today that two
abstracts summarizing data from clinical trials with its vascular disrupting
agent (VDA) product candidates, fosbretabulin (referred to as combretastatin
A4-phosphate / CA4P) and OXi4503, will be presented in posters at the upcoming
2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in
Chicago, IL, May 30-June 3, 2008. Two additional abstracts containing
fosbretabulin clinical trials data are published in the ASCO meeting program.
ASCO Poster Presentations:
Abstract #3550: A phase I study of combretastatin A4 phosphate
(CA4P) and bevacizumab in subjects with advanced solid tumors.
Poster presentation by Paul Nathan, MBBS, PhD, FRCP, Consultant
Medical Oncologist, Mount Vernon Cancer Centre, Northwood,
Middlesex, United Kingdom, on Sunday, June 1, 2008,
Developmental Therapeutics: Molecular Therapeutics, S Hall A1,
Poster 22B, 2:00-6:00 p.m.
Abstract #3551: Phase I evaluation of vascular disrupting
agent OXi4503. Poster presentation by Daniel M. Patterson, MD,
Department of Medical Oncology, Mount Vernon Hospital,
Northwood, Middlesex, United Kingdom on Sunday, June 1, 2008,
Developmental Therapeutics: Molecular Therapeutics, S Hall A1,
Poster 22F, 2:00-6:00 p.m.
Abstracts Published in the ASCO Annual Meeting Program:
Abstract #14584: Volumetric perfusion CT assessment of
concurrent combretastatin-A4-phosphate (CA4P) and
radiotherapy (RT) in non-small cell lung cancer.
H. C. Mandeville, V. Goh, Q. S. Ng, J. Milner,
M. I. Saunders, P. J. Hoskin.
Abstract #14517: A phase I/II trial of radioimmunotherapy
with 131Iodine labeled A5B7 anti-CEA antibody (131I-A5B7) in
combination with Combretastatin-A4-Phosphate (CA4P) in advanced
gastrointestinal carcinomas. A. M. Gaya, J. Violet,
G. Dancey, A. Green, M. Stratford, S. Sharma, K. Owen,
A. Padhani, G. J. Rustin, R. H. Begent, T. Meyer.
About ZYBRESTAT
ZYBRESTAT (fosbretabulin) is currently being evaluated in a pivotal registration
study as a potential treatment for anaplastic thyroid cancer (ATC) under a
Special Protocol Assessment agreement with the U.S. Food and Drug Administration
(FDA). Phase II studies in platinum-resistant ovarian cancer and non-small cell
lung cancer are also ongoing. OXiGENE believes that ZYBRESTAT is poised to
become the first therapeutic product in a novel class of small-molecule drug
candidates called vascular disrupting agents (VDAs). Through interaction with
vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets
and collapses tumor vasculature, thereby depriving the tumor of oxygen and
causing death of tumor cells. In clinical studies in solid tumors, ZYBRESTAT has
demonstrated potent and selective activity against tumor vasculature, as well as
clinical activity against ATC, ovarian cancer, and various other solid tumors.
In clinical studies in patients with forms of macular degeneration,
intravenously-administered ZYBRESTAT has demonstrated clinical activity, and the
Company is working to develop a convenient and patient-friendly topical
formulation of ZYBRESTAT for ophthalmological indications.
About OXi4503
OXi4503 (combretastatin A1 di-phosphate / CA1P) is a dual-mechanism VDA that is
being developed in clinical studies for the treatment of solid and liquid
tumors. Like its structural analog, ZYBRESTAT(TM) (fosbretabulin / CA4P),
OXi4503 has been observed to block and destroy tumor vasculature, resulting in
extensive tumor cell death and necrosis. In addition, preclinical data indicates
that OXi4503 is metabolized by oxidative enzymes (e.g., tyrosinase and
peroxidases), which are elevated in many solid tumors and tumor white blood cell
infiltrates, to an orthoquinone chemical species that has direct cytotoxic
effects on tumor cells. Preclinical studies have shown that OXi4503 has (i)
single-agent activity against a range of xenograft tumor models; and (ii)
synergistic or additive effects when incorporated in various combination
regimens with chemotherapy, molecularly-targeted therapies (including
tumor-angiogenesis inhibitors), and radiation therapy. OXi4503 is currently
being evaluated as a monotherapy in a Phase I dose-escalation clinical trial in
patients with advanced solid tumors.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing VDAs that selectively disrupt abnormal blood vessels associated with
solid tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property and therapeutic development expertise to
bring life-extending and -enhancing medicines to patients.
The OXiGENE, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=4969
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release may turn out to be wrong.
Forward-looking statements can be affected by inaccurate assumptions OXiGENE
might make or by known or unknown risks and uncertainties, including, but not
limited to, enrollment rate for patients in the ZYBRESTAT pivotal trial for
anaplastic thyroid cancer, interim analysis of the same, timing of the IND
filing and Phase I trial initiation for topical ZYBRESTAT, timing of a Phase II
clinical trial of ZYBRESTAT and bevacizumab in NSCLC, timing or execution of a
strategic collaboration on any product or indication, and cash utilization rates
for 2008. Additional information concerning factors that could cause actual
results to materially differ from those in the forward-looking statements is
contained in OXiGENE's reports to the Securities and Exchange Commission,
including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE
undertakes no obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise. Please refer to our
Annual Report on Form 10-K for the fiscal year ended December 31, 2007.
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
(415) 315-9413
medwards@oxigene.com
OXiGENE Announces Clinical Trials Data to be Presented At the 2008
| Source: Oxigene, Inc.